Gador S.A.
Records under this name other than the patents Gador S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,560,490 | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof Term ended Term ended Dec 20, 2022 · From the USPTO record | Term ended | Term ended Dec 20, 2022 | From the USPTO record |
| US 8,853,187 | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof Term ended Term ended Jun 12, 2022 · From the USPTO record | Term ended | Term ended Jun 12, 2022 | From the USPTO record |
| US 6,605,603 | Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid Term ended Term ended Jul 27, 2021 · From the USPTO record | Term ended | Term ended Jul 27, 2021 | From the USPTO record |
| US 7,846,474 | Use of bisphosphonates for the treatment of osteogenesis imperfecta Lapsed on the fee record Ended Dec 7, 2018 · From the USPTO record | Lapsed on the fee record | Ended Dec 7, 2018 | From the USPTO record |
| US 6,864,228 | Use of bisphosphonates for the treatment of osteogenesis imperfecta Lapsed on the fee record Ended Mar 8, 2017 · From the USPTO record | Lapsed on the fee record | Ended Mar 8, 2017 | From the USPTO record |
| US 8,153,648 | Solid and crystalline dutasteride and processes for preparation thereof Lapsed on the fee record Ended Apr 10, 2016 · From the USPTO record | Lapsed on the fee record | Ended Apr 10, 2016 | From the USPTO record |
| US 7,345,183 | Process for obtaining norelgestromin in different relations of isomers E and Z Lapsed on the fee record Ended Mar 18, 2012 · From the USPTO record | Lapsed on the fee record | Ended Mar 18, 2012 | From the USPTO record |
| US 6,476,223 | Method for obtaining N-[3(3-cyano-pyrazole[1,5-a]pyrimidine-7-yl)phenyl]-N-ethyl-acetamide Lapsed on the fee record Ended Nov 5, 2010 · From the USPTO record | Lapsed on the fee record | Ended Nov 5, 2010 | From the USPTO record |
| US 6,416,737 | Increasing bone strength with selected bisphosphonates Lapsed on the fee record Ended Jul 9, 2010 · From the USPTO record | Lapsed on the fee record | Ended Jul 9, 2010 | From the USPTO record |
| US 5,885,973 | Bone mass anabolic composition comprising olpadronate Formerly held Term ended Term ended no later than Mar 23, 2019 · Low confidence | Term ended | Term ended no later than Mar 23, 2019 | Low confidence |